Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical Business ReviewThe IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. RegulatoryOncologyRead full story Post navigation Previous: FDA points to liver injury with Amgen’s TavneosNext: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
